Introduction: Previous studies have demonstrated gender differences in risk of sudden death in patients with ischemic heart disease. The Multicenter UnSustained Tachycardia Trial (MUSTT) evaluated the ability of therapy guided by electrophysiologic (EP) testing to reduce mortality in patients with coronary disease, ejection fraction ≤40%, and spontaneous nonsustained ventricular tachycardia.
Introduction
Previous studies have raised concern regarding possible gender bias with respect to evaluation and treatment of cardiovascular disease, including referral for diagnostic cardiac catheterization, thrombolytic therapy for acute myocardial infarction (MI), and revascularization procedures for coronary artery disease. [1] [2] [3] [4] [5] [6] Women have greater morbidity and mortality associated with MI. 7 It has been suggested that there is gender bias in referral for invasive treatment, and this may have an impact on outcome. However, these gender differences in referral for invasive procedures or differences in outcome are explained, at least in part, on the basis of age, severity of coronary disease, or presence of other concomitant risk factors. [7] [8] [9] [10] Gender differences in the incidence of sudden death and risk factors for development of sustained ventricular arrhythmias have been previously described. 11, 12 The incidence of sudden cardiac death is lower in women than in men, comprising one third of all coronary heart disease deaths in women compared to one half in men. 11 There appears to be a 20-year lag in the incidence of sudden cardiac death in women in comparison to men. 12 This may be due to the protective effects of sex steroids on development of coronary artery disease.
The Multicenter UnSustained Tachycardia Trial (MUSTT) was a primary prevention trial that demonstrated the benefit of electrophysiologically (EP)-guided therapy for patients with coronary artery disease, reduced left ventricular function, and asymptomatic nonsustained ventricular tachycardia (NSVT). 13 Patients with inducible sustained ventricular tachycardia (VT) had a high mortality rate, which was lowered by treatment with implantable cardioverter defibrillators (ICDs) but not by antiarrhythmic drug therapy. The purpose of the current analysis was to determine the influence of gender on patient characteristics, treatment, and outcome of patients enrolled into this trial.
Methods
The MUSTT protocol has been described previously. 13, 14 This was a National Institutes of Health-sponsored, multicenter, randomized trial that evaluated the role of EP-guided antiarrhythmic therapy in patients with inducible sustained ventricular arrhythmias. Patients were eligible for enrollment if they had coronary artery disease, left ventricular ejection fraction (LVEF) ≤40%, asymptomatic NSVT, and no history of spontaneous sustained VT, syncope, or cardiac arrest, except in the setting of an acute MI. Patients who had inducible sustained VT were randomized to a standard medical regimen, which included treatment with beta-blockers and angiotensin-converting enzyme inhibitors, versus the same regimen with the addition of EP-guided therapy. EP-guided therapy included antiarrhythmic drug treatment or ICD therapy for patients who did not respond to antiarrhythmic drugs at the time of EP testing.
Patients were eligible for randomization if they had sustained monomorphic VT that was reproducibly inducible with single, double, or triple extrastimuli, or with burst pacing. If sustained polymorphic VT was reproducibly inducible with single or double extrastimuli, patients were eligible for randomization. Patients who refused randomization after induction of sustained VT were followed in a registry. Patients without any inducible sustained ventricular arrhythmias also were followed in the registry. In addition, patients with sustained polymorphic VT inducible with triple extrastimuli were not eligible for randomization and were followed in a registry.
Patients
A total of 2,202 patients were enrolled in the trial at 85 sites, including 704 patients with inducible sustained VT who were randomized as described earlier. The remaining 1,498 patients were followed in a registry without antiarrhythmic therapy.
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Statistical Analysis
Values for continuous variables are presented as medians with 25th and 75th percentiles. Values for categorical variables are presented as percentages. Differences in clinical characteristics and discharge medications between gender groups were assessed using the Wilcoxon rank sum test (for continuous variables) and the Chi-square test (for categorical variables). All tests of significance were two tailed. Cumulative event rates and survival curves were calculated by the Kaplan-Meier method, and outcome differences were assessed with the log rank test. In addition, covariate-adjusted analyses of outcomes were performed with the Cox proportional hazards model. Covariates included in these analyses were the induction of randomizable VT, age, ejection fraction, race, prior bypass surgery, prior angioplasty, prior MI, number of vessels with >75% stenosis, duration (in beats) of the longest episode of NSVT, symptoms of angina within 6 weeks of enrollment, left bundle branch block, intraventricular conduction delays, and use of digitalis at baseline. Hazard ratios and 95% confidence intervals also were calculated using the Cox proportional hazards model. 
Results
Overall Population: Randomized Versus Registry
A total of 301 women were enrolled in the trial, representing 14% of the total study population ( Table 1) . Ten percent of patients enrolled in the randomized group were women, whereas 16% of those in the registry were women (P = 0.001). Enrollment refusal forms were received from 856 patients (660 men and 160 women). Of the patients who refused enrollment, 10% of women and 15% of men underwent a baseline EP study (P = 0.083). For patients who underwent baseline EP testing in the enrollment refusal group, 86% of women and 65% of men had inducible sustained VT (P = 0.098). For those who refused enrollment, 19% of women compared to 10% of men were non-Caucasian (P = 0.002). Sufficient information regarding specific reasons for enrollment refusal is not available to allow adequate comparisons between men and women.
Baseline Characteristics
Within the randomized group, there were no significant differences in LVEF, race, presence of three-vessel coronary artery disease, prior coronary artery bypass graft or other revascularization, ECG conduction delays, or left ventricular hypertrophy between men and women ( Table 2) . Women were older, more likely to have had an MI within 6 months of enrollment, more likely to have experienced angina within 6 weeks prior to enrollment, and less likely to have atrial fibrillation than men.
Within the registry, there were no significant differences with regard to age, presence of three-vessel coronary artery disease, or percentage of patients who experienced angina within 6 weeks prior to enrollment in men and women. However, women had a higher LVEF and were more often nonCaucasian, less likely to have undergone prior coronary artery bypass graft or other revascularization, more likely to have suffered an MI within 6 months of enrollment, and more likely to have a left bundle branch block than men (Table 2) .
Although data regarding the clinical history of congestive heart failure (CHF) were not collected on all patients, for patients in whom data were available, there was a significant difference in the prevalence of CHF between men and women in the randomized group. In the randomized patients, 88% of females and 69% of males had a history of CHF (P = 0.008). In registry patients, 75% of females and 67% of males had a history of CHF (P = 0.111).
EP Testing
Men were more likely to have inducible sustained VT than women. Thirty-six percent of men versus 24% of women had inducible randomizable VT (P = 0.001). It should be noted that the higher percentage of women in the registry is due at least in part to this higher noninducibility rate in women. There was no difference in the type of VT induced in the randomized group. Ninety percent of men and 91% of women had sustained monomorphic VT induced; the remainder had sustained polymorphic VT induced (P = NS). Similarly, in registry patients, there was no difference in the percentage of men or women who had inducible sustained monomorphic VT.
Nonantiarrhythmic Medical Therapy
In the EP-guided therapy group, women were more likely to be discharged on diuretic therapy than men (Table 3) . Except for diuretic therapy, there were no other differences between men and women with respect to discharge nonantiarrhythmic medical therapy in the EP-guided therapy versus no EP-guided therapy group. In the registry, women were more likely to be discharged on calcium channel blockers, digoxin, diuretics, and nitrates than men (P < 0.05; Table 3 ).
Antiarrhythmic Drug Therapy
Among patients randomized to EP-guided therapy, 32% of women were discharged with pharmacologic antiarrhythmic therapy versus 46% of men (P = 0.12). There were no significant differences between men and women with respect to the number of antiarrhythmic drug trials or percentage of men versus women who still had inducible sustained ventricular arrhythmias after the first and last antiarrhythmic drug trials in the EP-guided therapy group. There was no difference between men and women with regard to the type of antiarrhythmic agents utilized.
Outcome: Arrhythmic Death or Cardiac Arrest
There were no gender differences in event-free survival from arrhythmic death or cardiac arrest in either the randomized or the registry patients (Fig. 1, Table 4 ). Within the randomized group, there were no differences in survival free of arrhythmic death or cardiac arrest between men and women who received EP-guided therapy or in those who received no EP-guided therapy (Table 4) .
Outcome: Total Mortality
There were no significant gender differences in all-cause mortality in either the randomized or the registry patients (Table 4 , Fig. 2 ). There was a trend toward a slightly higher overall mortality in women compared to men in the registry (27% vs 20%) and those who received EP-guided therapy (32% vs 21%), although this was not significant (adjusted P = 0.13 and 0.15, respectively). Within the randomized group, there were no differences in mortality between men and women who received EP-guided therapy and between men and women who received no EP-guided therapy. The interaction of treatment and gender was not significant (P = 0.12). 
Treatment: Type of EP-Guided Therapy and ICD Implantation
The type of therapy prescribed to men and women in the EP-guided therapy group was examined. At the time of hospital discharge, there was no significant difference between women and men with respect to the percentage of patients for whom ICDs were recommended in the EP-guided therapy group (21/ At the time of hospital discharge, 45% of men and 53% of women had received ICDs in the EP-guided therapy group (P = 0.38). An additional 41 men (13%) received ICDs after hospital discharge; 23 were implanted after an event (cardiac arrest, sustained VT, or syncope), and the remaining 18 were implanted for unknown reasons. No women received ICDs after hospital discharge. Thus, a total of 58% of men and 53% for induction of randomizable ventricular tachycardia, age, ejection fraction, race, prior myocardial infarction, prior coronary artery bypass graft surgery, prior percutaneous intervention (PCI) , number of diseased vessels (>75% stenosed), digitalis at baseline, intraventricular conduction delay, left bundle branch block, angina within 6 weeks of enrollment, longest episode of nonsustained ventricular tachycardia. †Noninducible registry patients.
of women had ICDs implanted at some point during the study (P = 0.57).
Discussion
We have demonstrated that gender influences many important characteristics of patients enrolled in MUSTT. In spite of these differences, the risk of mortality and arrhythmic events in the trial appears to be similar for men and women. However, it should be recognized that a lack of power, particularly regarding arrhythmic events and mortality, could prevent identification of a significant difference in outcome, due to the small number of women enrolled.
The reason why a relatively small percentage of women was enrolled in this trial likely is related to the higher prevalence of coronary artery disease in men. A significantly higher percentage of women was enrolled in the registry compared to the randomized group, reflecting the lower rate of inducing randomizable VT in women. However, the contribution of a higher refusal rate of women for enrollment in the randomized group or physician bias cannot be excluded, because complete refusal data are not available. Enrollment refusal also may be confounded by racial differences, as a higher percentage of non-Caucasian women compared to men refused enrollment.
Gender differences in baseline characteristics have been identified previously in cardiac arrest survivors. [15] [16] [17] [18] Studies have shown that women cardiac arrest survivors have a lower prevalence of coronary disease and may have a higher LVEF than men. [15] [16] [17] In the Antiarrhythmics Versus Implantable Defibrillator (AVID) trial, women were younger, more likely to have a nonischemic dilated cardiomyopathy, and more likely had ventricular fibrillation rather than VT as the index arrhythmia. 15 In the current study, women in the randomized group were older and more likely to have experienced a recent MI or recent angina than men. The use of nonantiarrhythmic drugs, such as digitalis and diuretics, was higher in women. There was a significantly higher prevalence of a history of CHF in women compared to men in the randomized group. We also found that women were less likely to have inducible sustained ventricular tachyarrhythmias, which is similar to results of previous retrospective studies. With respect to the type of EP-guided therapy, we did not observe gender bias related to ICD implantation rates in the current primary prevention trial. This is similar to previous secondary prevention trials, which demonstrated no significant gender differences in ICD implantation rates. 15, 16 In the present study, there were no differences with respect to ICD recommendations or refusal in women compared to men. In contrast, women refused ICD implantation more often than men (19% vs 2%, P = 0.01) in one previous study. 21 In the current study, there appeared to be no gender differences with regard to overall mortality or occurrence of arrhythmic death or cardiac arrest, despite gender differences in baseline characteristics and inducibility. Similar to the current analysis, mortality was similar in women (14.4%) and men (15.5%) in AVID, a secondary prevention trial, despite gender differences in baseline characteristics and clinical arrhythmia at the time of presentation. 15 In a retrospective review of patients enrolled in clinical studies designed to evaluate new ICDs or defibrillation leads, Pires et al. 22 demonstrated that men and women with a variety of clinical presentations and types of heart disease had similar sudden and cardiac deathfree survival rates during a mean follow-up period of <1 year. Consistent with the current study, MADIT II demonstrated that the benefit of defibrillator therapy on survival was similar in men and women with coronary disease who underwent device implantation for primary prevention. 23 
Study Limitations
This is a post hoc analysis of patients enrolled in MUSTT. The greatest limitation of this analysis is the small number of women enrolled in the trial, particularly the small number of women who received ICDs. Therefore, small differences in outcome may not be apparent.
Conclusion
Marked differences in inducibility of sustained VT, as well as other differences in characteristics between men and women, were observed in this trial. Despite these gender differences, EP-guided therapy, which includes a relatively "nonspecific" treatment with ICD implantation, appears to offer equal protection against arrhythmic death in men and women. Although the small number of women in this trial makes it difficult to draw any firm conclusions regarding gender differences in outcome, these results should be viewed as interesting preliminary data that are hypothesis-generating for examination in future trials. Risk stratification in women may need to be reconsidered to reflect that fact that women less often have inducible VT and often have a higher ejection fraction despite a more frequent history of heart failure. Further investigation also is warranted to determine whether gender differences in outcome might be apparent with different arrhythmia substrates or other types of heart disease, including patients with nonischemic dilated cardiomyopathy. Other multicenter primary prevention trials, such as the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), may help answer these questions.
